Phase 2 Trial of Tau Antibody RO7105705 Recruiting Patients with Moderate Alzheimer's

February 27, 2019

AC Immune CEO Andrea Pfeifer encouraged to see Genentech broaden its clinical evaluation of RO710570, a monoclonal antibody designed to stop the cell-to-cell spared of toxic forms of Tau protein.

Read the article in English: Article